263 related articles for article (PubMed ID: 21945397)
21. 11beta-hydroxysteroid dehydrogenase type 1 and obesity.
Morton NM; Seckl JR
Front Horm Res; 2008; 36():146-164. PubMed ID: 18230901
[TBL] [Abstract][Full Text] [Related]
22. Emodin, an 11β-hydroxysteroid dehydrogenase type 1 inhibitor, regulates adipocyte function in vitro and exerts anti-diabetic effect in ob/ob mice.
Wang YJ; Huang SL; Feng Y; Ning MM; Leng Y
Acta Pharmacol Sin; 2012 Sep; 33(9):1195-203. PubMed ID: 22922341
[TBL] [Abstract][Full Text] [Related]
23. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy.
Wang M
Handb Exp Pharmacol; 2011; (203):127-46. PubMed ID: 21484570
[TBL] [Abstract][Full Text] [Related]
24. Anti-diabetic and anti-inflammatory effect of a novel selective 11β-HSD1 inhibitor in the diet-induced obese mice.
Park SB; Jung WH; Kang NS; Park JS; Bae GH; Kim HY; Rhee SD; Kang SK; Ahn JH; Jeong HG; Kim KY
Eur J Pharmacol; 2013 Dec; 721(1-3):70-9. PubMed ID: 24135201
[TBL] [Abstract][Full Text] [Related]
25. Dehydroepiandrosterone 7alpha-hydroxylation in human tissues: possible interference with type 1 11beta-hydroxysteroid dehydrogenase-mediated processes.
Hennebert O; Chalbot S; Alran S; Morfin R
J Steroid Biochem Mol Biol; 2007 May; 104(3-5):326-33. PubMed ID: 17467270
[TBL] [Abstract][Full Text] [Related]
26. The environmental obesogen bisphenol A promotes adipogenesis by increasing the amount of 11β-hydroxysteroid dehydrogenase type 1 in the adipose tissue of children.
Wang J; Sun B; Hou M; Pan X; Li X
Int J Obes (Lond); 2013 Jul; 37(7):999-1005. PubMed ID: 23090578
[TBL] [Abstract][Full Text] [Related]
27. Effects of bile acids on rat hepatic microsomal type I 11beta-hydroxysteroid dehydrogenase.
Maeda Y; Naganuma S; Niina I; Shinohara A; Koshimoto C; Kondo K; Chijiiwa K
Steroids; 2010 Feb; 75(2):164-8. PubMed ID: 19948178
[TBL] [Abstract][Full Text] [Related]
28. The functional consequences of 11beta-hydroxysteroid dehydrogenase expression in adipose tissue.
Tomlinson JW; Stewart PM
Horm Metab Res; 2002; 34(11-12):746-51. PubMed ID: 12660893
[TBL] [Abstract][Full Text] [Related]
29. Human adipose tissue under in vitro inhibition of 11beta-hydroxysteroid dehydrogenase type 1: differentiation and metabolism changes.
Bader T; Zoumakis E; Friedberg M; Hiroi N; Chrousos GP; Hochberg Z
Horm Metab Res; 2002; 34(11-12):752-7. PubMed ID: 12660894
[TBL] [Abstract][Full Text] [Related]
30. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?
Anagnostis P; Katsiki N; Adamidou F; Athyros VG; Karagiannis A; Kita M; Mikhailidis DP
Metabolism; 2013 Jan; 62(1):21-33. PubMed ID: 22652056
[TBL] [Abstract][Full Text] [Related]
31. A novel highly potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, UI-1499.
Byun SY; Shin YJ; Nam KY; Hong SP; Ahn SK
Life Sci; 2015 Jan; 120():1-7. PubMed ID: 25447448
[TBL] [Abstract][Full Text] [Related]
32. Pharmacological evaluation of adipose dysfunction via 11β-hydroxysteroid dehydrogenase type 1 in the development of diabetes in diet-induced obese mice with cortisone pellet implantation.
Akiyama N; Akiyama Y; Kato H; Kuroda T; Ono T; Imagawa K; Asakura K; Shinosaki T; Murayama T; Hanasaki K
J Pharmacol Exp Ther; 2014 Apr; 349(1):66-74. PubMed ID: 24511146
[TBL] [Abstract][Full Text] [Related]
33. Upregulation of adipose 11-beta-hydroxysteroid dehydrogenase type 1 expression in ovariectomized rats is due to obesity rather than lack of estrogen.
Paulsen SK; Nielsen MP; Richelsen B; Bruun JM; Flyvbjerg A; Pedersen SB
Obesity (Silver Spring); 2008 Apr; 16(4):731-5. PubMed ID: 18379559
[TBL] [Abstract][Full Text] [Related]
34. 11Beta-hydroxysteroid dehydrogenase type 1 in human disease: a novel therapeutic target.
Tomlinson JW
Minerva Endocrinol; 2005 Mar; 30(1):37-46. PubMed ID: 15877012
[TBL] [Abstract][Full Text] [Related]
35. Active site variability of type 1 11beta-hydroxysteroid dehydrogenase revealed by selective inhibitors and cross-species comparisons.
Hult M; Shafqat N; Elleby B; Mitschke D; Svensson S; Forsgren M; Barf T; Vallgårda J; Abrahmsen L; Oppermann U
Mol Cell Endocrinol; 2006 Mar; 248(1-2):26-33. PubMed ID: 16431016
[TBL] [Abstract][Full Text] [Related]
36. Differential modulation of 3T3-L1 adipogenesis mediated by 11beta-hydroxysteroid dehydrogenase-1 levels.
Kim J; Temple KA; Jones SA; Meredith KN; Basko JL; Brady MJ
J Biol Chem; 2007 Apr; 282(15):11038-46. PubMed ID: 17311922
[TBL] [Abstract][Full Text] [Related]
37. The discovery of new 11beta-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening.
Schuster D; Maurer EM; Laggner C; Nashev LG; Wilckens T; Langer T; Odermatt A
J Med Chem; 2006 Jun; 49(12):3454-66. PubMed ID: 16759088
[TBL] [Abstract][Full Text] [Related]
38. 7-oxysterols modulate glucocorticoid activity in adipocytes through competition for 11beta-hydroxysteroid dehydrogenase type.
Wamil M; Andrew R; Chapman KE; Street J; Morton NM; Seckl JR
Endocrinology; 2008 Dec; 149(12):5909-18. PubMed ID: 18755798
[TBL] [Abstract][Full Text] [Related]
39. Role of 11-beta-hydroxysteroid dehydrogenase type 1 in differentiation of 3T3-L1 cells and in rats with diet-induced obesity.
Liu Y; Sun WL; Sun Y; Hu G; Ding GX
Acta Pharmacol Sin; 2006 May; 27(5):588-96. PubMed ID: 16626514
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of 11β-hydroxysteroid dehydrogenase type 1 in visceral adipose tissue and portal hypercortisolism in non-alcoholic fatty liver disease.
Candia R; Riquelme A; Baudrand R; Carvajal CA; Morales M; Solís N; Pizarro M; Escalona A; Carrasco G; Boza C; Pérez G; Padilla O; Cerda J; Fardella CE; Arrese M
Liver Int; 2012 Mar; 32(3):392-9. PubMed ID: 22136330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
